Cetilistat NEW

Factory Provide Body Management Cetilistat Powder CAS No 282526-98-1

Introduction

Product Name : Cetilistat

Other name:Cetilistat(Alt-962);Cetilstat;2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one;2-(Hexadecycloxy)-6-methyl-4H-3,1-benzoxazin-4-one;

CAS No.: 282526-98-1

Molecular Formula: C25H39NO3

Molecular Weight: 401.58

Specification:99%

Appearance: White powder or crystal 

Melting Point :72.0 to 76.0 °C

Boiling Point :509.7±43.0 °C(Predicted)

Density: 1.02

Storage :Sealed in dry,Room Temperature

Cetilistat (also known as ATL-962) was approved in September 2013 by the Japanese Ministry of Health, Labor and Welfare for the treatment of obesity, limited to patients with both type 2 diabetes mellitus (T2DM) and dyslipidemia, and with a body mass index (BMI)25 kg/m2 in spite of dietary treatment and/or exercise therapy. 

The medicinal chemistry program has not been described in the scientific literature, but the patent describing cetilistat also describes the synthesis of analogs with varied aryl substituents and lipophilic tails. The synthesis of cetilistat involves condensation of a hexadecylcarbonochloridate with 2-amino-5-methylbenzoic acid; other analogs were synthesized by varying the carbonochloridate and 2-aminobenzoic acid components. Cetilistat is a potent inhibitor of human and rat pancreatic lipase with IC50s of 15 and 136 nM, respectively, with little inhibition of trypsin or chymotrypsin.

Application

1. Cetilistat is a novel pancreatic lipase inhibitor for the treatment of obesity in both diabetic and non-diabetic patients.

2. Cetilistat is also called cetilistat, cetilistat, cetilista, off-white to white crystalline powder main uses: new weight loss drug, and can be applied to quit smoking; indications: new weight loss, quit smoking, lowering blood lipids, pharmaceutical raw materials.

3. Cetilistat is a long-acting and potent specific gastrointestinal lipase inhibitor that exerts its therapeutic effect by forming covalent bonds with the active serine sites of gastric lipase and pancreatic lipase in the lumen of the stomach and small intestine to inactivate the enzymes. The inactivated enzymes are unable to hydrolyze the fats in food, mainly triglycerides, into absorbable free fatty acids and monoacylglycerols, and undigested triglycerides cannot be absorbed by the body, thereby reducing caloric intake and controlling body weight.